Aetna modified CPB 0936 for ibalizumab-uiyk (Trogarzo), effective January 5, 2026. Here's what billing teams need to know.
Aetna, a CVS Health company, updated CPB 0936, its ibalizumab-uiyk (Trogarzo) coverage policy for adults with multidrug resistant HIV-1. The revised policy governs HCPCS code J1746 (injection, ibalizumab-uiyk, 10 mg) and related infusion administration codes (CPT 96365–96368 and CPT 96413–96417). If your practice or infusion center treats heavily treatment-experienced HIV patients and bills Aetna, this policy sets every coverage threshold your claims must clear.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Ibalizumab-uiyk (Trogarzo) — CPB 0936 |
| Policy Code | CPB 0936 |
| Change Type | Modified |
| Effective Date | January 5, 2026 |
| Impact Level | High — narrow patient population, strict four-part medical necessity test |
| Specialties Affected | Infectious disease, HIV specialty clinics, infusion centers, hospital outpatient |
| Key Action | Confirm all four medical necessity criteria are documented in the chart before submitting claims for J1746 on or after January 5, 2026 |
Aetna Ibalizumab-uiyk Coverage Criteria and Medical Necessity Requirements 2026
The Aetna ibalizumab-uiyk coverage policy under CPB 0936 applies only to adults with multidrug resistant (MDR) HIV-1 who are failing their current antiretroviral (ARV) regimen. This is not a broad HIV therapy policy. Aetna limits coverage to a very specific, last-resort population — and every criterion must be met simultaneously.
Aetna requires all four of the following conditions before it considers ibalizumab-uiyk (J1746) medically necessary:
| # | Covered Indication |
|---|---|
| 1 | Age: The member is 18 years old or older. |
| 2 | Viral load: Confirmed viral load greater than 1,000 copies/mL. |
| 3 | Documented resistance: Resistance to at least one ARV from each of three drug classes — NRTIs, NNRTIs, and Protease Inhibitors (PIs) — confirmed by resistance testing. |
| 4 | Treatment history: The member has been on ARV therapy for at least six months and is currently failing or recently failed (within the last eight weeks) their regimen. |
All four conditions must be satisfied. Missing even one triggers a medical necessity denial.
The three drug classes referenced in criterion three are defined explicitly in the policy. NRTIs include drugs like abacavir (Ziagen), lamivudine (Epivir), and zidovudine (Retrovir). NNRTIs include efavirenz (Sustiva), etravirine (Intelence), and rilpivirine (Edurant). PIs include atazanavir (Reyataz), darunavir (Prezista), and ritonavir (Norvir). These examples come directly from the clinical study eligibility criteria that the FDA used as the basis for Trogarzo's approval.
Resistance must be documented through resistance testing — not assumed from treatment history alone. Aetna's related policy CPB 0316 covers HIV drug susceptibility and resistance testing, so make sure the resistance test results are in the chart and that the resistance test itself was billed and covered before you submit the Trogarzo claim.
Reimbursement for the drug itself runs through J1746. Administration reimbursement runs through the infusion CPT codes. CPB 0936 references both IV infusion administration codes (96365–96368) and chemotherapy administration codes (96413–96417) as related codes. Consult your payer contract and coding guidelines to determine which administration code applies to your setting.
Aetna Ibalizumab-uiyk Exclusions and Non-Covered Indications
Aetna considers ibalizumab-uiyk experimental, investigational, or unproven for all indications outside the four-part medical necessity criteria above. The policy is explicit: insufficient peer-reviewed published literature supports any other use.
In practice, this means if your patient doesn't meet all four criteria — wrong age, suppressed viral load, incomplete resistance documentation, or insufficient treatment history — Aetna will not cover Trogarzo. There is no partial coverage pathway. There is no off-label use exception built into this policy.
This is a narrow coverage window by design. Ibalizumab-uiyk is a CD4-directed post-attachment HIV-1 inhibitor. It exists for patients who have exhausted options in multiple ARV classes. Aetna's coverage policy mirrors that clinical reality tightly.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| MDR HIV-1 in adults ≥18, viral load >1,000 copies/mL, resistance to NRTI + NNRTI + PI, failing ARV ≥6 months | Covered | J1746, B20, Z16.33 | All four criteria must be met simultaneously |
| Any use outside the four-part criteria above | Not Covered — Experimental/Investigational | J1746 | Insufficient peer-reviewed evidence per Aetna CPB 0936 |
| Pediatric use (under 18) | Not Covered | — | Age criterion explicitly requires 18 or older |
| HIV-1 with viral load ≤1,000 copies/mL | Not Covered | — | Viral load threshold is a hard stop |
| HIV-1 with resistance to fewer than three ARV classes | Not Covered | — | Must have documented resistance to NRTI, NNRTI, and PI |
Aetna Ibalizumab-uiyk Billing Guidelines and Action Items 2026
These steps apply to any practice, infusion center, or RCM team billing Aetna for Trogarzo on or after January 5, 2026.
| # | Action Item |
|---|---|
| 1 | Audit your active Trogarzo patients now. Pull every Aetna member currently receiving ibalizumab-uiyk. For each one, confirm all four medical necessity criteria are documented in the chart with dates. Do this before January 5, 2026, not after your first denial. |
| 2 | Verify resistance testing is on file. HCPCS J1746 claims will not hold up without documented resistance to at least one drug in each of the three classes — NRTI, NNRTI, and PI. The resistance test results should be in the chart, not just referenced in a progress note. ICD-10 code Z16.33 (resistance to antiviral drugs) should appear on your claims alongside B20 (HIV disease). |
| 3 | Bill J1746 with the correct diagnosis codes. Use B20 as your primary diagnosis for MDR HIV-1 disease. Add Z16.33 to flag antiretroviral resistance. Z21 covers asymptomatic HIV infection status with a multidrug resistant HIV-1 qualifier per the source policy — confirm with your treating provider which code applies to each patient before billing. |
| 4 | Pair J1746 with the right infusion administration codes. CPB 0936 lists both IV infusion administration codes (CPT 96365–96368) and chemotherapy administration codes (CPT 96413–96417) as related codes. Consult your payer contract and coding guidelines to determine which set applies to your billing setting and patient encounter type. |
| 5 | Confirm prior authorization requirements directly with Aetna. CPB 0936 does not specify a prior authorization process. That said, prior auth requirements for specialty injectables are typically set at the plan or contract level, not within the clinical policy bulletin itself. Check Aetna's portal or call the payer to confirm auth requirements for each member before the first infusion. This is standard operational due diligence — it is not derived from CPB 0936. |
| 6 | Document treatment failure clearly. Criterion four requires the member to be currently failing or to have recently failed (within the last eight weeks) their ARV regimen. "Recently" means within eight weeks of the Trogarzo start date. Your medical records need to show the date of treatment failure clearly. Vague chart notes like "not responding to current regimen" are not enough — you need dates, lab values, and the specific regimen that failed. |
| 7 | Flag new starts for compliance review. If you're initiating Trogarzo for a new Aetna patient after January 5, 2026, run the chart through your billing compliance officer before submitting the first claim. The four-part criteria is tight, and the financial exposure on a denied specialty drug claim is significant. If there's any ambiguity in how the criteria apply to a specific patient, get your compliance officer involved before the effective date of treatment, not after. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Ibalizumab-uiyk Under CPB 0936
Covered HCPCS Code (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J1746 | HCPCS | Injection, ibalizumab-uiyk, 10 mg |
CPT Administration Codes Referenced in CPB 0936
| Code | Type | Description |
|---|---|---|
| 96365 | CPT | Intravenous infusion administration |
| 96366 | CPT | Intravenous infusion administration |
| 96367 | CPT | Intravenous infusion administration |
| 96368 | CPT | Intravenous infusion administration |
| 96413 | CPT | Chemotherapy administration |
| 96414 | CPT | Chemotherapy administration |
| 96415 | CPT | Chemotherapy administration |
| 96416 | CPT | Chemotherapy administration |
| 96417 | CPT | Chemotherapy administration |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| B20 | Human immunodeficiency virus (HIV) disease — use for MDR HIV-1 infection |
| Z16.33 | Resistance to antiviral drug(s) — use to document resistance to NRTI, NNRTI, and PI |
| Z21 | Asymptomatic human immunodeficiency virus (HIV) infection status [multidrug resistant (MDR) HIV-1 infection] |
A note on the administration codes: CPB 0936 lists both IV infusion codes (CPT 96365–96368) and chemotherapy administration codes (CPT 96413–96417) as related codes. The policy does not specify which set to use for ibalizumab-uiyk administration. Your payer contract, your facility type, and your coding guidelines should drive that decision. If you're unsure which codes apply to your setting, talk to your compliance officer before billing.
Get the Full Picture for CPT 96365
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.